PR Newswire:
LifeVantage Corporation announced today that the Company’s flagship product, Protandim, a patented dietary supplement composed of five highly synergistic “indirect antioxidants”, is currently the subject of two human clinical trials at the University of Colorado, Denver. 
The studies, entitled The Effect of the Dietary Supplement Protandim on Non-Alcoholic Steatohepatitis: A Randomized, Double Blind, Placebo-Controlled Study and Double Blinded Placebo Controlled Trial of Protandim for Individuals With a History of Alcohol Abuse respectively, began enrolling patients earlier this year and are currently on-going. These two trials are now listed in the Clinical Trials Database, a registry of federally and privately supported clinical trials conducted in the United States and around the world. The database is provided as a service of the U.S. National Institutes of Health and is available for public access at www.clinicaltrials.gov.
This independent clinical study is investigating the effects of Protandim on Non-alcoholic Steatohepatitis (“NASH”). Patient recruitment in this study has begun and is by invitation only.
Logo from LifeVantage
